Beta
Back to RXRX.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
cash-and-debt-chart

RXRX Cash & Debt

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

As of Q4'25, RXRX's cash and short-term investments stood at $743M USD, reflecting a robust liquidity position, while total debt was $78M USD, resulting in a net cash surplus of approximately $665M USD. This latest data point indicates continued financial strength, with cash reserves significantly outpacing liabilities. Over the period from Q1'23 to Q4'25, cash and short-term investments exhibited volatility but an overall upward trend, starting at $473M USD and peaking at $743M USD after dipping to a low of $300M USD in Q1'24; notable growth occurred post-Q2'24, with increases of 38% in Q3'25 and 13% in Q4'25. In contrast, debt remained relatively stable around $50M-$90M USD until a sharp rise to $108M USD in Q4'24, followed by a steady decline to $78M USD by Q4'25, improving the net cash position from $420M USD in Q1'23 to its current high. This pattern suggests effective cash management and debt reduction, enhancing RXRX's balance sheet resilience for financial analysts monitoring biotech sector liquidity.